[Oxygen therapy in emergency and intensive care medicine]

Hyperoxia is Dose-Dependently Associated with an Increase of Unfavorable Outcomes in Ventilated Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study

Background

Adequate oxygenation in patients with aneurysmal subarachnoid hemorrhage (SAH) is imperative. However, hyperoxia increases formation of reactive oxygen species and may be associated with a dose-dependent toxicity. We postulated a threshold for arterial partial pressure of oxygen (paO₂) above which toxicity effects precipitate and sought to study the effects on 30-day mortality, favorable outcome at discharge and at 3 months, and delayed cerebral ischemia.

Methods

In this retrospective single-center cohort study, patients with SAH and mechanical ventilation > 72 h were included. Oxygen integrals were calculated above the following thresholds: 80, 100, 120, and 150 mm Hg and time-weighted mean paO₂. All calculations were done from admission to end of day 1, day 3, and day 14. We conducted multivariable logistic regression analyses adjusted for age, sex, duration of ventilation, and Hunt and Hess grade. Time-weighted mean paO₂ was categorized by quartiles. Favorable outcome was defined as Glasgow Outcome Scale scores of 4 and 5.

Results

From November 2010 to February 2021, 282 of 549 patients fulfilled the inclusion criteria. Odds ratios for 30-day mortality increased dose dependently and were as follows: 1.07 (95% confidence interval [CI] 1.03–1.11; p = 0.001) for each 1 mm Hg per day above 80 mm Hg; 1.16 (95% CI 1.07–1.27), above 100 mm Hg; 1.36 (95% CI 1.15–1.61), above 120 mm Hg; and 1.59 (95% CI 1.22–2.08), above 150 mm Hg (all p < 0.001) at day 14. For favorable outcome at 3 months, odds ratios were 0.96 (95% CI 0.92–0.99) for each 1 mm Hg per day above 80 mm Hg; 0.90 (95% CI 0.84–0.98), above 100 mm Hg; 0.83 (95% CI 0.72–0.97), above 120 mm Hg; and 0.77 (95% CI 0.61–0.97), above 150 mm Hg (all p < 0.05). For time-weighted mean paO₂, lowest 30-day mortality and highest favorable outcome at 3 months were found in the second quartile (78–85 mm Hg). Thirty-day mortality increased above 93 mm Hg (fourth quartile), with an odds ratio of 3.4 (95% CI 1.4–8.4, p = 0.007). Odds ratios for favorable outcome at 3 months were 0.28 (95% CI 0.12–0.69), 0.27 (95% CI 0.11–0.67), and 0.24 (95% CI 0.10–0.59) for the first, third, and fourth quartiles, respectively (all p < 0.01). No significant association was found at day 1 and day 3, for favorable outcome at discharge, or for delayed cerebral ischemia.

Conclusions

Integrals above the defined paO₂ thresholds were dose-dependently associated with an increase in mortality in ventilated patients with SAH. When we considered time-weighted mean paO₂, unfavorable outcomes and 30-day mortality were more frequent both below and above a certain range. Unfavorable outcomes increased in paO₂ ranges usually defined as normoxia. This emphasizes the necessity to further characterize oxygenation thresholds in ventilated patients with SAH in prospective clinical studies.

Supplementary Information

The online version contains supplementary material available at 10.1007/s12028-022-01534-y.

Home Monitoring of Oxygen Saturation Using a Low-Cost Wearable Device with Haptic Feedback to Improve Sleep Quality in a Lung Cancer Patient: A Case Report

This study reports the case of a lung cancer patient with increasing difficulties in falling asleep and frequent periods of wakefulness. Severe dyspnea related to pneumonitis caused as a side effect of immunotherapy worsened the situation. Eventually, a fear of falling asleep developed, including panic attacks and anxiety around choking, which was shown to lead to nights of complete wakefulness. The patient did not only sleep poorly; he did not sleep at all at night for several days, as evidenced by the notes he made during the night. Polygraphy showed no evidence of sleep-disordered breathing, but frequent periods of wakefulness and a reduced basal saturation of around 90% during sleep due to lung changes such as an extensive functional failure of the left upper lobe with position-dependent shunts. The authors hypothesized that the symptoms described were causally related to a drop in oxygen saturation in the patient’s blood. Therefore, they pursued the goal of finding a measurement technique that is as inexpensive as possible and that the patient can operate without outside assistance and great effort. Thus, the patient started using a low-cost wearable device that allows simultaneous measurements of blood oxygen content, pulse rate, and movement intensity. It consists of a finger ring with a pulse oximetry sensor and a wristband with a control unit containing a vibration motor. The described device reliably warned of disturbances in the oxygen concentration in the blood during the night with its vibration alarm. By use of that device during the whole night at home, the events of reduced oxygen saturation and anxiety symptoms were reduced. Sleep disturbances with sudden awakenings did not occur when using the device. The patient benefited from the security gained in this way and slept much more peacefully, and he could spend nights without waking up again. In conclusion, wearable oximeters with vibration alarms can be recommended for patients’ home care in lung cancer patients.

High-Flow-Sauerstofftherapie – Chancen und Risiken

Mit der High-Flow-Sauerstofftherapie („high flow nasal cannula“ [HFNC]), bei der ein Sauerstoff-Luft-Gasgemisch mit Flüssen zwischen 30 und 70 l/min appliziert wird, steht ein technisch einfaches und hocheffektives Verfahren zur Therapie einer respiratorischen Insuffizienz zur Verfügung. Des Weiteren kann die HFNC während einer Bronchoskopie zur Oxygenierung, vor einer Intubation zur Präoxygenierung und nach Extubation zur Vermeidung einer Re-Intubation verwendet werden. Durch die hohen Gasflüsse wird vermieden, dass der Patient Umgebungsluft inspiriert, sodass eine präzise Einstellung einer inspiratorischen Sauerstofffraktion möglich ist, des Weiteren wird durch einen entstehenden Staudruck ein positiver endexspiratorischer Druck aufgebaut, durch die Anfeuchtung und Erwärmung der Atemluft die mukoziliäre Clearance verbessert sowie die Atemarbeit durch Auswaschen der oberen Atemwege verringert. Im Vergleich zur konventionellen Sauerstofftherapie ist die Aerosolbildung durch eine HFNC nicht erhöht, sodass dieses Verfahren auch bei COVID-19 eingesetzt werden kann. Beim hyperkapnischen Lungenversagen liegen bisher keine konklusiven Daten für die Effekte der HFNC vor, hier sollte bevorzugt eine nichtinvasive Beatmung statt einer HFNC erfolgen. Bei der Anwendung darf nicht vergessen werden, dass die mit HFNC behandelten Patienten kritisch krank sind und daher kontinuierlich überwacht werden müssen. So muss sichergestellt sein, dass jederzeit eine Eskalation z. B. auf eine Intubation und invasive Beatmung erfolgen kann.